Bortezomib Market Size and Trends

Global bortezomib market is estimated to be valued at USD 24.54 Mn in 2024 and is expected to reach USD 33.15 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.

Bortezomib Market Key Factors

To learn more about this report, request sample copy

Global bortezomib market growth is driven by rising prevalence of multiple myeloma and growing adoption of bortezomib as a part of combination therapy. Moreover, robust pipeline of novel drug candidates and increasing demand for more effective targeted therapies can offer growth opportunities to market players. However, patent expirations of branded products and development of cheaper generics can hamper the market growth. Continuous research & development to develop safer and more effective drugs through collaborations can drive the market growth.

Increasing prevalence of multiple myeloma

Rising prevalence of multiple myeloma can drive the market growth. Multiple myeloma is a type of cancer that affects plasma cells, which are a type of white blood cell that helps the body to fight infections. The exact cause of multiple myeloma is not known but risk factors include genetics, family history and age. The chances of developing multiple myeloma increases with age and it is very rare in people under age 40 years. As life expectancy rises worldwide, the population of elderly people increases rapidly. Since multiple myeloma is predominantly a disease of older adults, the aging global population directly translates to a larger pool of susceptible individuals.

Rising prevalence of disease boosts demand for drugs for treat multiple myeloma. Currently bortezomib remains one of the most effective and commonly prescribed drugs for multiple myeloma. Multiple myeloma causes bone lesions and destroys bone tissues. It also suppresses the bone marrow and reduces the production of healthy blood cells. If left untreated, multiple myeloma can be fatal within a few months. With rising disease burden, there has been increase in requirement for effective treatment options like bortezomib. Countries with aging populations and better access to healthcare are witnessing a sharp rise in multiple myeloma cases. This growth in patient base has steadily boosted the sales and demand for bortezomib in these regions over the past decade.

Growing adoption of bortezomib for treating multiple myeloma

Bortezomib was the first proteasome inhibitor approved for the treatment of multiple myeloma and it marked a major breakthrough in the management of the disease. Bortezomib is a vital part of the standard treatment regimens for multiple myeloma across all stages and forms. It has demonstrated superiority over other options in improving survival rates and delaying disease progression. Due to its well-established safety profile and significant clinical benefits, bortezomib has gained widespread acceptance amongst both patients and treating physicians over the years. Moreover, availability of bortezomib as both injectable and oral formulations has further increased patient convenience and compliance. Bortezomib is now used at various stages of multiple myeloma including induction therapy, autologous stem cell transplantation, consolidation therapy and for relapsed or refractory multiple myeloma. It is often administered along with other classes of drugs like immunosuppressants to achieve better disease control and response rates. Clinicians continuously expand the scope of bortezomib therapy based on emerging clinical evidence. For example, its use as a maintenance therapy and in combination with immunomodulators are newer approved indications. The improving accessibility to sophisticated treatments and rising affordability have also played a role in augmenting the uptake of bortezomib globally. As more real-world data underpins its clinical utility, adoption is expected to scale to a wider patient pool worldwide in the future.